Development and validation of an Arabic version of the International Prostate Symptom Score
Authors:
- 27 April 2010
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 105 (10) , 1434-1438
Abstract
OBJECTIVE: To develop and validate an Arabic version of the International Prostate Symptom Score (IPSS). PATIENTS, SUBJECTS AND METHODS: An Arabic version of the IPSS (IPSS‐Arb) was developed through a series of translations and modifications which involved the authors, urology and non‐urology medical and nursing staff. The validity and reliability were assessed in 76 patients with urinary symptoms due to benign prostatic hyperplasia (BPH) and in 63 control subjects without BPH; 25 patients had transurethral resection of prostate (TURP) whereas the remaining 51 patients were treated with terazosin. The reliability of the IPSS‐Arb was assessed by determining the internal consistency (Cronbach’s α coefficient) and by assessing the test‐retest reliability (intraclass correlation coefficient, ICC). Construct validity was assessed by determining the correlation between the IPSS‐Arb scores and the quality‐of‐life question (QoL‐Arb), and by determining the ability of the IPSS‐Arb to discriminate between the patients and controls by calculating the area under the receiver operating characteristic (ROC) curve. RESULTS: The Cronbach’s α coefficient (internal consistency) for the IPSS‐Arb was 0.85, and 0.78–0.88 for the individual items. The test‐retest reliability (ICC) was 0.88 ( P < 0.001). In addition, the IPSS‐Arb had a high correlation with the QoL‐Arb (Spearman rank correlation coefficient 0.82, P = 0.01). The mean ( sem , 95% confidence interval) area under the ROC curve for the IPSS‐Arb was 0.93 (0.09, 0.89–0.97), whereas the area for its individual questions was 0.79–0.90. The IPSS‐Arb also showed a high sensitivity to change. The mean ( sd ) IPSS‐Arb scores before and after TURP were 23.1 (6.4) and 6.9 (1.8), respectively ( P < 0.001); in the terazosin group, the scores were 12.6 (7.4) and 8.2 (4.0), respectively ( P < 0.001). CONCLUSIONS: The IPSS‐Arb was shown to be a reliable and valid instrument for patients with BPH. We recommend using it for patient assessment and follow‐up, and as a research tool in Arabic‐speaking patients both in the Middle East and worldwide. In addition, this study provided another proof of the wide suitability of the IPSS among various nations worldwide.Keywords
This publication has 10 references indexed in Scilit:
- Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or olderInternational Urology and Nephrology, 2008
- Reliability and validity of the International Prostate Symptom Score in a Malaysian populationBJU International, 2001
- A 3‐year follow‐up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomyBJU International, 2000
- A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1‐year follow‐upBJU International, 1999
- Validation of a harmonized Spanish version of the IPSS: evidence of equivalence with the original American scaleUrology, 1998
- Ten-Language Translation and Harmonization of the International Prostate Symptom Score: Developing a Methodology for Multinational Clinical TrialsEuropean Urology, 1997
- The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasiaUrology, 1996
- A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic HyperplasiaJournal of Urology, 1992
- The American Urological Association Symptom Index for Benign Prostatic HyperplasiaJournal of Urology, 1992
- Epidemiology and Natural History of Benign Prostatic HyperplasiaUrologic Clinics of North America, 1990